Companies within the biotechnology industry are very interesting to investors because they see wild swings in share price following positive or negative news, particularly in the case of small biotech companies. Investing in biotech and other pharmaceutical stocks can be risky because their price action can be so swift and unpredictable.Investors looking for some riskier options for their portfolio biotech companies may be a good choice due to the possibility of significant upside. But, it is best to have l ...

Financial Data and Key Metrics Changes - For Q3 2023, total revenues reached $380.9 million, up from $252.4 million year-over-year, reflecting a 51% increase [7] - GAAP net income was $47.8 million, while non-GAAP net income was $109.5 million for the quarter [10] - The company ended the quarter with approximately $996 million in cash and total investments, and total debt outstanding of approximately $291 million [10] Business Line Data and Key Metrics Changes - VIVITROL net sales were $99.3 million, reflecting a 3% year-over-year growth driven by alcohol dependence indication [7][16] - ARISTADA product family net sales increased 8% year-over-year to $81.8 million, primarily due to underlying demand [7][16] - LYBALVI net sales for the quarter were $50.7 million, up 8% sequentially, with a 10% growth in underlying prescriptions [8][14] Market Data and Key Metrics Changes - Manufacturing and royalty revenues were $149.1 million, compared to $52.9 million in the same period last year, driven by long-acting INVEGA products [8] - Revenues from VUMERITY were $34.6 million, up from $26.3 million year-over-year [9] Company Strategy and Development Direction - The company plans to separate its oncology business into Mural Oncology, which is expected to enhance profitability and focus on neuroscience [11][37] - Post-separation, Alkermes aims to be a pure play neuroscience company with a strong balance sheet and a focus on strategic priorities, including the ALKS 2680 development program [11][38] - The company is committed to disciplined expense management while investing in growth opportunities [11][38] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the potential for enhanced profitability following the favorable outcomes of recent legal matters and the upcoming separation of the oncology business [6][10] - The company reiterated its financial expectations for 2023, reflecting combined neuroscience and oncology business performance [10] Other Important Information - Initial clinical data for ALKS 2680, a novel orexin 2 receptor agonist for narcolepsy, was presented, showing promising safety and efficacy profiles [19][33] - The company is focused on executing brand strategies for its proprietary products and driving net sales expectations for 2023 [18] Q&A Session Summary Question: How will long-term durability be factored into dosing for the orexin program? - Management indicated that they will model appropriate doses for Phase 2 based on observed dose response and safety profiles [41][42] Question: What is the plan for idiopathic hypersomnia (IH) development? - The company is collecting data on IH patients and will inform appropriate doses for Phase 2 based on these data [45][47] Question: Can you comment on the commercial organization as a leverageable asset? - Management confirmed that the established commercial infrastructure can be leveraged for additional products, indicating openness to acquiring market-ready assets [48] Question: What are the safety concerns regarding blood pressure increases observed in patients? - Management noted that only transient increases in blood pressure were observed, with no significant safety signals identified [67] Question: What are the expectations for LYBALVI trends into next year? - Management expressed confidence in LYBALVI's growth prospects, citing expanding prescriber breadth and ongoing direct-to-consumer campaigns [55]

Third Quarter 2023 Financial Results & Business Update October 25, 2023 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 https://reportify- 1252068037.cos.ap- beijing.myqcloud.com/media/produ ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its cha ...

Second Quarter 2023 Financial Results & Business Update July 26, 2023 ...

Alkermes plc (NASDAQ:ALKS) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Corporate Affairs and Investor Relations Iain Brown – Chief Financial Officer Todd Nichols – Chief Commercial Officer Richard Pops – Chief Executive Officer Conference Call Participants Chris Shibutani – Goldman Sachs David Amsellem – Piper Sandler Paul Matteis – Stifel Umer Raffat – Evercore ISI Uy Ear – Mizuho Securities Marc Goodman – Leerink Partners Jason Gerbe ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 https://reportify- 1252068037.cos.ap- beijing.myqcloud.com/media/produ ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) ...

Call Start: 08:00 January 1, 0000 9:01 AM ET Alkermes plc (NASDAQ:ALKS) Q1 2023 Earnings Conference Call April 26, 2023 08:00 ET Company Participants Sandra Coombs - Senior Vice President of Investor Relations & Corporate Affairs Richard Pops - Chief Executive Officer Iain Brown - Chief Financial Officer Todd Nichols - Chief Commercial Officer Conference Call Participants Akash Tiwari - Jeffries Brandon Folkes - Cantor Fitzgerald Umer Raffat - Evercore ISI Chris Shibutani - Goldman Sachs David Amsellem - Pi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35299 ALKERMES PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 98-1007018 (State or other jurisdiction of incorporation or o ...

Fourth Quarter and Year-End 2022 Financial Results & Business Update February 16, 2023 © 2021 Alkermes. All rights reserved. © 2023 Alkermes. All rights reserved. Forward-Looking Statements and Non-GAAP Financial Information Certain statements set forth in this presentation constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: Alkermes plc's (the "Company") expectations concerning ...